Reply: Potential role of Janus kinase inhibitors in COVID-19 - 19/06/20
Funding sources: None. |
|
Conflicts of interest: Dr Napolitano has acted as a speaker for Sanofi. Dr Fabbrocini has acted as a speaker and consultant for AbbVie and LEO Pharma. Dr Patruno has acted as a speaker and consultant for AbbVie, Novartis, Pfizer, and Sanofi. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 83 - N° 1
P. e65 - juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.